Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response prediction. The role of soluble CD40 (sCD40) is unknown in PDAC. In this study, we performed a quantitative multiple...
Alternative Titles
Full title
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c19f5bd9248f4e8393bbb8bdfd097f13
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c19f5bd9248f4e8393bbb8bdfd097f13
Other Identifiers
ISSN
2397-768X
E-ISSN
2397-768X
DOI
10.1038/s41698-023-00459-9
